Yan Wu

Yan Wu

Auto-generated profile, based on publicly available information

Yan Wu

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
ZTZhichao Tan
Zhichao Tan
YWYan Wu
Yan Wu
ZFZhengfu Fan
Zhengfu Fan
TGTian Gao
Tian Gao
WGWei Guo
Wei Guo
JLJiayong Liu
Jiayong Liu
Purpose: Alveolar soft part sarcoma (ASPS) is an ultrarare soft-tissue sarcoma with a high rate of metastasis and no established treatment. This study aimed to explore the efficacy and safety of anlotinib (a tyrosine kinase inhibitor) and TQB2450 (a PD-L1 inhibitor) in patients with ASPS. Patients and Methods: This single-arm, phase II study evaluated the efficacy of TQB2450, an anti–PD-L1 agent, combined with anlotinib, a tyrosine kinase inhibitor, in adults with advanced ASPS. TQB2450 was given intravenously (1,200 mg) on day 1, and anlotinib (12 mg/day) was taken orally from day 1 to 14 every 3 weeks. The primary endpoint was overall response rate, with secondary endpoints including duration of response, progression-free survival, and overall survival. Lymphocyte infiltration and tertiary lymphoid structure (TLS) were also analyzed as potential prognostic biomarkers. Results: The study enrolled 29 patients, of whom 28 were evaluable (one withdrew because of acute pancreatitis). An objective response was achieved in 82.1% of patients, including 4 complete and 19 partial responses. The median time to response was 2.8 months, and the duration of response was not reached, with an estimated median progression-free survival of 35.2 months. Grade 3 to 4 treatment-related adverse events occurred in 44.8% of patients, with no study-related deaths. Responders had a higher proportion of TLS area, TLS density, and CD20-positive immune cells. Conclusions: The combination of anlotinib and TQB2450 is effective and tolerable in patients with ASPS. TLS may serve as a prognostic biomarker, meriting further investigation.

31 August 2020 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
XCXiao Yan Chang
Xiao Yan Chang
YWYan Wu
Yan Wu
YJYing Jiang
Ying Jiang
PWPeng Yan Wang
Peng Yan Wang
JCJie Chen
Jie Chen
An intraductal papillary mucinous neoplasm (IPMN) is a common pancreatic precursor lesion, and it often harbors mutations in KRAS, GNAS, and RNF43. To clarify the molecular profiles of IPMNs, we conducted mutation analysis of KRAS, GNAS, and RNF43 in 61 IPMN formalin-fixed, paraffin-embedded (FFPE) specimens. The mutation rates of codons 12, 13, and 61 in KRAS and codon 201 in GNAS were detected by Sanger sequencing. Next-generation sequencing was performed on RNF43, and the results were further verified by Sanger sequencing. We identified KRAS and GNAS mutations in 35 (57%) and 40 (66%) IPMN cases, respectively. GNAS mutations were significantly correlated with the morphologic subtype (P<0.001) and were more prevalent in the intestinal subtype (93%) than in the gastric (55%) and pancreatobiliary subtypes (44%) but were absent in the oncocytic subtype. RNF43 mutations were found in 5 cases (8%), all of which occurred in high-grade dysplasia and invasive lesions (2/5 and 3/5). All 5 cases harboring RNF43 mutations also exhibited GNAS mutations. RNF43 mutations were associated with a worse prognosis in invasive IPMN patients (P=0.002), while KRAS and GNAS mutations did not affect the prognosis of patients.

8 July 2020 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
XYXu Yang
Xu Yang
NLNan LI
Nan LI
TGTingting Guo
Tingting Guo
XGXiaoyuan Guan
Xiaoyuan Guan
JTJiang-Shan Tan
Jiang-Shan Tan
HLHong Liu
Hong Liu

9 November 2022 in Human Pathology
Verified
Journal Article
Closed access
YWYan Wu
Yan Wu
HLHuan Li
Huan Li
LTLuxin Tan
Luxin Tan
YLYumei Lai
Yumei Lai
ZLZhongwu Li
Zhongwu Li

26 January 2021 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
TWTongbo Wang
Tongbo Wang
YWYan Wu
Yan Wu
HZHong Zhou
Hong Zhou
CWChaorui Wu
Chaorui Wu
XZXiaojie Zhang
Xiaojie Zhang
DZDongbing Zhao
Dongbing Zhao
Background: Adenocarcinoma in Esophagogastric Junction (AEG) is a severe gastrointestinal malignancy with a unique clinicopathological feature. Hence, we aimed to develop a competing risk nomogram for predicting survival for AEG patients and compared it with new 8th traditional tumor-node-metastasis (TNM) staging system. Methods: Based on data from the Surveillance, Epidemiology, and End Results (SEER) database of AEG patients between 2004 and 2010, we used univariate and multivariate analysis to filter clinical factors and then built a competing risk nomogram to predict AEG cause-specific survival. We then measured the clinical accuracy by comparing them to the 8th TNM stage with a Receiver Operating Characteristic (ROC) curve, Brier score, and Decision Curve Analysis (DCA). External validation was performed in 273 patients from China National Cancer Center. Results: A total of 1755 patients were included in this study. The nomogram was based on five variables: Number of examined lymph nodes, grade, invasion, metastatic LNs, and age. The results of the nomogram was greater than traditional TNM staging with ROC curve (1-year AUC: 0.747 vs. 0.641, 3-year AUC: 0.761 vs. 0.679, 5-year AUC: 0.759 vs. 0.682, 7-year AUC: 0.749 vs. 0.673, P < 0.001), Brier score (3-year: 0.198 vs. 0.217, P = 0.012; 5-year: 0.198 vs. 0.216, P = 0.008; 7-year: 0.199 vs. 0.215, P = 0.014) and DCA. In external validation, the nomogram also showed better diagnostic value than traditional TNM staging and great prediction accuracy. Conclusion: We developed and validated a novel nomogram and risk stratification system integrating clinicopathological characteristics for AEG patients. The model showed superior prediction ability for AEG patients than traditional TNM classification.

13 August 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
ZTZhichao Tan
Zhichao Tan
JRJiayin Ruan
Jiayin Ruan
YWYan Wu
Yan Wu
ZFZhengfu Fan
Zhengfu Fan
CBChujie Bai
Chujie Bai
JLJiayong Liu
Jiayong Liu
Purpose: Alveolar soft part sarcoma (ASPS) is an ultrarare soft tissue sarcoma. Current standard therapy with PD-1/PD-L1 inhibitors achieves limited response rates (<40%). Lymphocyte-activation gene 3 (LAG-3) is coexpressed with PD-1 on exhausted T cells, and dual blockade has shown synergy in some solid tumors but remains unexplored in sarcoma. This trial evaluated the efficacy of IBI110 (anti–LAG-3) plus sintilimab (anti–PD-1) in advanced ASPS. Patients and Methods: This open-label, phase II study enrolled 28 patients from July 2022 to September 2023 (median follow-up, 33.6 months). Both drugs were given intravenously at 200 mg every 3 weeks. The primary endpoint was overall response rate (ORR) by RECIST v1.1. Results: Among 28 patients, 8 (28.6%) were resistant to prior immune checkpoint inhibitors (ICI), and 20 (71.4%) were ICI-naïve. The overall ORR was 51.8% (14/27 evaluable), including 4 complete responses and 10 partial responses. During a median follow-up of 33.6 months, the median progression-free survival (PFS) and overall survival (OS) were not reached in the whole population. In ICI-naïve patients, the ORR was 60%, with median PFS/OS not reached. In ICI-resistant patients, the ORR was 25%, with median PFS of 14.9 months and median OS of 25.4 months. The median time to response was 3.3 months; the median duration of response (DoR) was not reached. Grade 3 to 4 treatment-related adverse events occurred in nine patients (32.1%), with no treatment-related deaths. Exploratory analysis showed that responders had significantly higher baseline LAG-3+ cell density in tumor specimens. Conclusions: Dual LAG-3/PD-1 blockade demonstrated promising and durable antitumor activity with manageable safety in both ICI-naïve and ICI-resistant advanced ASPS, warranting further investigation.